|Bid||73.57 x 300|
|Ask||73.58 x 900|
|Day's Range||73.24 - 73.79|
|52 Week Range||52.83 - 75.99|
|Beta (3Y Monthly)||0.60|
|PE Ratio (TTM)||151.15|
|Earnings Date||Jan 31, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||2.20 (2.94%)|
|1y Target Est||79.12|
Risk markets continue to deliver mixed messages to traders and market participants. The latest price action suggests more downside -- but first -- with a possible bounce to the 2750 level in the S&P 500, says Yahoo Finance's Jared Blikre, who breaks it down with Jen Rogers and Myles Udland. Here's the month-to-date performance of the components of the Dow Jones Industrial Average as of 11/14/2018: PG Procter & Gamble Co -0.21% VZ Verizon Communications -0.60% KO Coca-Cola Co -0.38% AXP American Express Co -0.73% DIS Disney (Walt) Co -0.43% JNJ Johnson & Johnson -1.01% MRK Merck & Co -0.68% WBA Walgreen Boots Alliance Inc -0.37% MCD McDonald's Corp -0.79% DWDP DowDuPont Inc 0.03% UTX United Technologies -0.93% CAT Caterpillar Inc 0.39% MMM 3M Co 0.14% NKE Nike Inc Cl B -2.11% INTC Intel Corp 0.25% IBM Intl Business Machines Corp 0.05% V Visa Inc -0.35% PFE Pfizer Inc -0.52% CVX Chevron Corporation -1.78% HD Home Depot Inc -1.55% $INDU Dow Jones Industrial Average -0.47% JPM JPMorgan Chase & Co 0.77% WMT Wal-Mart Stores -1.31% UNH UnitedHealth Grp Inc -0.83% MSFT Microsoft Corp 0.36% XOM Exxon Mobil -1.19% CSCO Cisco Systems 4.17% TRV The Travelers Companies Inc -0.23% BA Boeing Co -1.19% AAPL Apple Inc 0.99% GS Goldman Sachs Grp -0.14%
AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 13) AstraZeneca plc (NYSE: AZN ) Down In The Dumps (Biotech ...
Merck & Co's blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday. Keytruda, among a class of medicines called PD-1 inhibitors, is Merck's top selling drug and has already been approved to treat several forms of cancer including skin and lung cancer. Keytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.
With Pivotal KEYNOTE-181 Trial Meeting Primary Endpoint of OS, KEYTRUDA Becomes the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit for These Patients
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed over the past few years. However, hedge funds are generally partially hedged and […]
Merck (MRK), known as MSD outside the United States and Canada, today announced that it has started the submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for V920 (rVSV∆G-ZEBOV-GP, live attenuated), the company’s investigational vaccine for Ebola Zaire disease. This rolling submission is made pursuant to the FDA’s Breakthrough Therapy Designation for V920, which was announced by the company in July 2016.
After Democrats obtained a narrow majority in the House of Representatives in the midterm elections, both House Democrats and President Trump will likely be looking to make at least some deals. To retain their majority, House Democrats will have to convince moderate voters in the swing districts that Democrats narrowly won that they are moderate and can be productive. For his part, President Trump will likely have to convince at least some moderate voters, i.e., centrist suburban women and independents that he can make deals that will make the country and their lives better.